Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial

Ken M. Kunisaki, Dennis E. Niewoehner, Gary Collins, Bitten Aagaard, Nafisah B. Atako, Elzbieta Bakowska, Amanda Clarke, Giulio Maria Corbelli, Ernest Ekong, Sean Emery, Elizabeth B. Finley, Eric Florence, Rosa M. Infante, Cissy M. Kityo, Juan Sierra Madero, Daniel E. Nixon, Ellen Tedaldi, Jørgen Vestbo, Robin Wood, John E. Connettfor the INSIGHT START Pulmonary Substudy Group

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Background Observational data have been conflicted regarding the potential role of HIV antiretroviral therapy (ART) as a causative factor for, or protective factor against, COPD. We therefore aimed to investigate the effect of immediate versus deferred ART on decline in lung function in HIV-positive individuals. Methods We did a nested substudy within the randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial at 80 sites in multiple settings in 20 high-income and low-to-middle-income countries. Participants were HIV-1 infected individuals aged at least 25 years, naive to ART, with CD4 T-cell counts of more than 500 per μL, not receiving treatment for asthma, and without recent respiratory infections (baseline COPD was not an exclusion criterion). Participants were randomly assigned to receive ART (an approved drug combination derived from US Department of Health and Human Services guidelines) either immediately, or deferred until CD4 T-cell counts decreased to 350 per μL or AIDS developed. The randomisation was determined by participation in the parent START study, and was not specific to the substudy. Because of the nature of our study, site investigators and participants were not masked to the treatment group assignment; however, the assessors who reviewed the outcomes were masked to the treatment group. The primary outcome was the annual rate of decline in lung function, expressed as the FEV1 slope in mL/year; spirometry was done annually during follow-up for up to 5 years. We analysed data on an intention-to-treat basis, and planned separate analyses in smokers and non-smokers because of the known effects of smoking on FEV1 decline. The substudy was registered at ClinicalTrials.gov number NCT01797367. Findings Between March 11, 2010, and Aug 23, 2013, we enrolled 1026 participants to our substudy, who were then randomly assigned to either immediate (n=518) or deferred (n=508) ART. Median baseline characteristics included age 36 years (IQR 30–44), CD4 T-cell count 648 per μL (583–767), and HIV plasma viral load 4·2 log10 copies per mL (3·5–4·7). 29% were female and 28% were current smokers. Median follow-up time was 2·0 years (IQR 1·9–3·0). We noted no differences in FEV1 slopes between the immediate and deferred ART groups either in smokers (difference of −3·3 mL/year, 95% CI −38·8 to 32·2; p=0·86) or in non-smokers (difference of −5·6 mL/year, −29·4 to 18·3; p=0·65) or in pooled analyses adjusted for smoking status at each study visit (difference of −5·2 mL/year, −25·1 to 14·6; p=0·61). Interpretation The timing of ART initiation has no major short-term effect on rate of lung function decline in HIV-positive individuals who are naive to ART, with CD4 T-cell counts of more than 500 per μL. In light of updated WHO recommendations that all HIV-positive individuals should be treated with ART, regardless of their CD4 T-cell count, our results suggest an absence of significant pulmonary harm with such an approach. Funding US National Heart Lung and Blood Institute, US National Institute of Allergy and Infectious Diseases, Division of AIDS, Agence Nationale de Recherches sur le SIDA et les Hipatites Virales (France), Australian National Health and Medical Research Council, Danish National Research Foundation, European AIDS Treatment Network, German Ministry of Education and Research, UK Medical Research Council and National Institute for Health Research, and US Veterans Health Administration Office of Research and Development.

Original languageEnglish (US)
Pages (from-to)980-989
Number of pages10
JournalThe Lancet Respiratory Medicine
Volume4
Issue number12
DOIs
StatePublished - Dec 1 2016

Bibliographical note

Funding Information:
The study team expresses our immense gratitude to each of the individual 1026 START Pulmonary Substudy participants for their contributions to our scientific understanding of lung disease in HIV. A full listing of START Pulmonary Substudy team members is included in the appendix and a full listing of the parent START study team members can be found in the primary results publication. The START Pulmonary Substudy reported here was supported by the National Heart Lung and Blood Institute (R01 HL096453); the parent START trial was primarily supported by the National Institute of Allergy and Infectious Diseases Division of AIDS (UM1 AI068641 and UM1 AI120197) with additional support from Agence Nationale de Recherches sur le SIDA et les Hipatites Virales (France), the Danish National Research Foundation, the German Ministry of Education and Research, the European AIDS Treatment Network, the Australian National Health and Medical Research Council, and the UK Medical Research Council and National Institute for Health Research. The Veterans Health Administration Office of Research and Development also provided protected research time in support of this study. The University of Minnesota served as sponsor of the study. Permission to use the St George's Respiratory Questionnaire for COPD was granted to investigators by Paul Jones (St George's, University of London, London, UK). Antiretroviral drugs were donated by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck. The views expressed in this article are those of the authors and do not reflect the views of the US Government, the National Institutes of Health, the Department of Veterans Affairs, the funders, or any of the authors' affiliated academic institutions.

Funding Information:
KMK, DENie, GC, BA, NBA, EB, AC, EE, SE, EBF, EF, RMI, CMK, JSM, DENix, ET, RW, and JEC received grant support from the National Institutes of Health ( R01 HL096453, UM1 AI068641, and UM1 AI120197 ) for doing this study. Outside this study: DENie has received personal fees from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline; GMC has received personal fees from Gilead Sciences and ViiV Healthcare; AC has received other support from Bristol-Myers Squibb, Gilead Sciences, and Janssen; JSM has received grants from Bristol-Myers Squibb, Pfizer and ViiV Healthcare, and personal fees from Gilead Sciences, MSD, Pfizer, and Stendhal; and JV reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline, and Novartis. SE has received grant support from the Australian National Health and Medical Research Council and ViiV Healthcare, and personal fees from Merck Research Laboratories and Mylan Laboratories.

Publisher Copyright:
© 2016 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial'. Together they form a unique fingerprint.

Cite this